IL37 and metabolic dysfunction-associated steatotic liver disease: Importantly, on histological examination, we observed that anti-IL-23 treatment prevented the development of steatosis, ballooning, lobular inflammation, and reduced NAFLD scores in Atg5 CD11cKO mice when compared to isotype controls (Fig. 6i, j).